Literature DB >> 16987259

Basal cell carcinoma arising over facial port wine stain: a single-centre experience.

M Lapidoth1, D Ad-El, M David, J Alcalay, R Azaria.   

Abstract

BACKGROUND: A growing number of reports point to a possible connection between basal cell carcinoma (BCC) and port wine stain (PWS). Researchers suggest that either the elevated temperature induced by the increased dermal vasculature or an oncogenic factor produced by the ectatic vessels makes the overlying epidermis more susceptible to ultraviolet or ionizing radiation.
OBJECTIVE: To check the prevalence of BCC in patients with PWS at a large national vascular amomalies centre.
METHODS: The study group included 68 patients, 44 women and 24 men, with facial PWSs. Detailed data were collected on background features, past treatments and past exposure to radiation, and a comprehensive physical examination was performed. Biopsy samples were taken from suspect lesions for histological study.
RESULTS: Four patients (5.9%) were found to have histologically proven BCC, 3 nodular and one multifocal. All had been exposed to radiation during childhood. Treatment consisted of excision; there was one recurrence.
CONCLUSION: Although the co-occurrence of BCC and PWS is probably related to radiation treatment in childhood, these findings should alert physicians to regularly examine PWSs for cancerous changes, especially in patients at risk.

Entities:  

Mesh:

Year:  2006        PMID: 16987259     DOI: 10.1111/j.1468-3083.2006.01701.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  2 in total

1.  [Basal cell carcinomas in radiotherapy-treated port wine stains. An ideal indication for Mohs surgery].

Authors:  E Sattler; H-C Räwer; M Mühlstädt; T Ruzicka; W Burgdorf; C Kunte
Journal:  Hautarzt       Date:  2011-07       Impact factor: 0.751

2.  Basal cell carcinoma arising in port wine stains: coincidence or correlation?

Authors:  Iwona Chlebicka; Aleksandra Stefaniak; Andrzej Bieniek; Jacek Szepietowski
Journal:  Postepy Dermatol Alergol       Date:  2020-05-06       Impact factor: 1.837

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.